The J.P. Morgan event is known as the event for biotech and the investor community and, although typically aimed at generalists, bio journalists are always on…

As his inauguration nears, Donald Trump has interviewed an eclectic mix of candidates for his pick as National Institutes of Health (NIH) chief.

German Merck and U.S. software firm Palantir have teamed up on big data to help the pharma to combine its research with other bioinformatics.

The belief that the FDA is to undergo a major shift in thinking was given further credence as another curveball was thrown into the mix.

Kitov Pharmaceuticals has bought a 56% stake in TyrNovo to take control of a cancer program.

Nivalis is laying off 80% of its staff including its CEO and CMO.

CV9014 failed a phase 2b trial in prostate cancer, but the company says its efficacy could be unlocked if used alongside checkpoint inhibitors.

Biogen’s new spinoff Bioverativ will be trading on the Nasdaq next from the start of month with two products, $325 million in the bank, hundreds of staffers…

Ionis, fresh from its approval of Spinraza with Biogen, says it is seeking to get its heart drug volanesorsen in front of the FDA as soon as possible, as it…